Skip to main navigation Educational Grants Investigator Studies Patient Support Services Contact Us Biosimilars Products & Pipeline Investors Join Our Team Patient Support Services Contact Us OVERVIEW News Events & Presentations Stock Information Financials Corporate Governance Shareholder Services Shareholder Tools Investors A FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY WITH A ROBUST PIPELINE ACROSS MULTIPLE THERAPEUTIC AREAS. Coherus is a commercial stage biopharmaceutical company with the mission to increase patient access to cost-effective medicines that can have a major impact on their lives and to deliver significant savings to the health care system. In January 2021, Coherus in-licensed Junshi Biosciences’ toripalimab, an anti-PD-1 antibody, which will be a cornerstone of Coherus’ strategy to build a leading immuno-oncology franchise in the United States and Canada funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved. Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies. News 11/15/21 Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer 11/10/21 Coherus BioSciences Announces New Employment Inducement Grants 11/08/21 Coherus BioSciences Reports Third Quarter 2021 Results 11/05/21 Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022 View All Events & Presentations Q3 2021 Coherus BioSciences, Inc. Earnings Conference Call Monday November 08, 2021 at 5:00 PM EST View All Investor Presentation Columbus-AMD Clinical Trial Data at Scientific Meeting of the Retina Society JUPITER-06 Interim Data at ESMO Congress 2021 About Coherus Leadership Team Board of Directors Scientific Advisory Board Immuno-oncology Scientific Advisory Board Commercial Advisory Committee Contact Us Immuno-oncology Toripalimab Program Biosimilars Unique Development Process FDA Approval Process Products and Pipeline UDENYCA® (pegfilgrastim-cbqv) Coherus COMPLETE™ Medical Information Investors Join Our Team Openings Privacy Notice Contact Us Coherus uses cookies on this website. They help us to know a little bit about you and how you use our website. Privacy Notice Site Map Contact Us Join Our Team Copyright © 2021 Coherus BioSciences, Inc.